Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : RBC Capital Adjusts Merck & Company PT to $77 From $79, Maintains Sector Perform Rating

04/30/2021 | 10:58am EDT


ę MT Newswires 2021
All news about MERCK & CO., INC.
03:09pMERCK : Keeps Quarterly Dividend at $0.65 per Share, Payable Oct. 7 to Sharehold..
MT
01:35pMERCK : Announces Fourth-Quarter 2021 Dividend
BU
12:52pMERCK : Truist Assumes Merck & Company at Buy Rating With $92 Price Target
MT
09:07aMERCK : Wins US FDA Approval For Breast Cancer Drug
MT
06:46aMERCK : Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Surv..
BU
06:31aMERCK : FDA Approves KEYTRUDA« (pembrolizumab) for Treatment of Patients With Hi..
BU
05:42aMerck's Keytruda Hits Key Endpoint in Metastatic Triple-Negative Breast Cance..
DJ
04:59aMerck Gets FDA Expanded OK for Keytruda in Breast Cancer
DJ
07/23MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combinat..
AQ
07/22ADAGENE : Agrees With Merck on Trials of Its Monoclonal Antibodies With Keytruda..
MT
More news
Financials (USD)
Sales 2021 46 551 M - -
Net income 2021 12 867 M - -
Net Debt 2021 11 752 M - -
P/E ratio 2021 16,5x
Yield 2021 3,39%
Capitalization 196 B 196 B -
EV / Sales 2021 4,45x
EV / Sales 2022 4,05x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 77,24 $
Average target price 94,10 $
Spread / Average Target 21,8%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-5.57%195 576
JOHNSON & JOHNSON9.21%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.13.58%234 040
NOVARTIS AG-0.17%221 954
ELI LILLY AND COMPANY44.05%221 084